Status:
UNKNOWN
Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study
Lead Sponsor:
Tanta University
Conditions:
Esophageal Varices
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to compare the efficacy of 2-days versus 5-days octreotide infusion after endoscopic therapy in preventing early esophageal varices rebleed in patients with cirrhosis.
Detailed Description
Variceal hemorrhage, causative of 70% of all upper gastrointestinal (GIT) bleeding events in patients with portal hypertension, remains one of the most severe and immediate life-threatening complicati...
Eligibility Criteria
Inclusion
- Acute esophageal varices bleeding
- Liver cirrhosis
Exclusion
- Initial failure to control variceal bleed on endoscopy
- Other causes of GIT bleeding
- Hepatocellular carcinoma
- Portal vein thrombosis
- Renal dialysis and hepatorenal syndrome
- History of myocardial infarction
- Pregnancy or lactation
- Allergy to octreotide
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT05199038
Start Date
June 1 2022
End Date
November 1 2023
Last Update
May 18 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.